Cumulus Oncology Raises £9M in Seed Financing

Cumulus Oncology, an Edinburgh-based oncology biotech company, raised £9 million in Seed funding led by Eos Advisory and the Scottish National Investment Bank. The funding will be used to expand the company's portfolio and accelerate the development of new cancer treatments. Cumulus identifies novel targets for drug discovery programs and spins out selected assets into new companies. The company utilizes AI and ML platforms in its decision-making process and manages each spinout company to achieve key development milestones. Its first company, Nodus Oncology, is currently engaged in two innovative oncology drug discovery programs. A second company is set to be unveiled in early 2024.

Cumulus Oncology Secures £9 Million Seed Funding to Advance Cancer Treatments

Cumulus Oncology is an Edinburgh, Scotland, UK-based oncology biotech company that sources novel oncology assets from academic institutes, commercial drug discovery groups and biopharmaceutical companies. Its scientific and commercial team members identify novel targets for drug discovery programs which the company funds, supports and collaborates on. Following due diligence and market assessment activities, negotiations on deal terms and in-depth feasibility on the investment case, selected assets are spun out into newly created companies. An early focus on molecularly selected patient sub-groups, is a key aspect of the business model. The company incorporates the use of artificial intelligence (AI) and machine learning (ML) platforms into its decision making process to prioritise targets and assets. It contributes both early-stage capital and oncology drug development expertise and manages each spinout company to achieve key development milestones and value inflections. The companies created by Cumulus represent valuable investment opportunities for VCs that focus on the biotech sector. These VCs are important partners for it when the spinout companies reach key inflection points.

Cumulus Oncology is an Edinburgh, Scotland, UK-based oncology biotech company that sources novel oncology assets and spins them out into new companies.

2 years ago

Cumulus Oncology Secures £9 Million Seed Funding to Advance Cancer Treatments

ProblemHealthcare

Solution

Covered on